HCPLive

Heart Failure Total Cost Estimated at $70 Billion by 2030

THURSDAY, April 25 (HealthDay News) -- The impact of heart failure is likely to increase, with more than eight million U.S. adults anticipated to have heart failure by 2030, at an estimated total cost of $70 billion, according to a study published online April 24 in Circulation: Heart Failure.

Paul A. Heidenreich, MD, from Stanford University, in California, and colleagues estimated the epidemiology and future costs of heart failure from 2012 to 2030, based on a model that assumes heart failure prevalence will remain constant and that the costs and technological innovation will continue to increase at the same rate.

The researchers projected that more than eight million people in the Unites States will have heart failure by 2030. The direct costs of medications are expected to increase from $21 billion in 2012 to $53 billion in 2030. The estimated total costs, including indirect costs, are expected to increase from $31 billion to $70 billion. Assuming all costs of cardiac care for patients with heart failure are attributable to heart failure, and not to comorbid conditions, the cost estimates projected for 2030 would be $160 billion in direct costs.

"Assuming continuation in present practice patterns, the cost of heart failure is projected to increase markedly over the next 18 years based on demographic changes in the population," the authors write. "The cost would be substantial, with each U.S. adult, on average, paying $244 annually by 2030 to care for the 10 million patients with heart failure."

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract
Full Text

Copyright © 2013 HealthDay. All rights reserved.

Most Popular

Recommended Reading

For patients with adolescent idiopathic scoliosis (AIS), surgeons are allowing return to sports starting at three months after corrective surgery, according to research published in the May 1 issue of The Spine Journal.

For patients with suspected pulmonary embolism (PE), computed tomography (CT) pulmonary angiography is superior to chest radiography for providing a diagnosis, even when no PE is present; however, in patients at low risk, the clinical benefit is questionable, according to a study published in the May issue of the Annals of the American Thoracic Society.

Caution should be exercised with use of electronic health record (EHR) documentation short cuts, according to a report published in Medical Economics.

Potential mechanisms for the antiatherosclerotic activity of methotrexate (MTX) and adalimumab in rheumatoid arthritis (RA) have been identified, according to a study published in the May issue of Arthritis & Rheumatology.

$vAR$